Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
| Status: | Completed |
|---|---|
| Conditions: | Dermatology, Hair Loss |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | November 2008 |
| End Date: | June 2010 |
Phase II Double-Blind, Placebo-Controlled Study of the Safety and Preliminary Effectiveness of MTS-01 for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this
can contribute to the distress and social isolation of patients with advanced cancer. In
this study a topical gel will be applied directly to the scalp during each dose of
radiotherapy. The goal is to determine to what extent the experimental drug is successful in
lessening the hair loss.
can contribute to the distress and social isolation of patients with advanced cancer. In
this study a topical gel will be applied directly to the scalp during each dose of
radiotherapy. The goal is to determine to what extent the experimental drug is successful in
lessening the hair loss.
Inclusion Criteria:
- Metastatic cancer to the brain for which palliative whole brain radiotherapy is
recommended.
- Hair that covers the scalp and is at least 1/4 inch in length
Exclusion Criteria:
- Receiving chemotherapy known to cause alopecia within 60 days of study or during the
study.
- Pre-existing alopecia
- Previous brain radiotherapy
- scalp metastases or scalp wounds
- use of hair dyes
We found this trial at
2
sites
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
University of Arizona The University of Arizona is a premier, public research university. Established in...
Click here to add this to my saved trials